{
    "nctId": "NCT02460744",
    "briefTitle": "2-weeks of Adjuvant Radiotherapy in Patients With Breast Cancer",
    "officialTitle": "A Phase II Study of 2-weeks of Adjuvant Whole Breast/Chest Wall and/or Regional Nodal Radiotherapy in Patients With Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 50,
    "primaryOutcomeMeasure": "acute skin and subcutaneous toxicity assessed using a RTOG grading system",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* invasive carcinoma of the breast\n* breast conservation surgery or mastectomy (reconstruction allowed but not with implant. Tissue expanders with distant metal ports are allowed)\n* axillary staging \\&/or dissection\n* complete microscopic excision of primary tumour\n* pT1-3 pN0-2 M0 disease\n* written informed consent\n* able to comply with follow up N.B. Concurrent trastuzumab and hormone therapy is allowed\n\nExclusion Criteria:\n\n* past history of malignancy except (i) basal cell skin cancer and CIN cervix uteri or (ii) non-breast malignancy allowed if treated with curative intent and at least 5 years disease free\n* contralateral breast cancer, including DCIS, irrespective of date of diagnosis\n* breast reconstruction using implants\n* concurrent cytotoxic chemotherapy (sequential neoadjuvant or adjuvant cytotoxic therapy allowed)",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}